Corvus Pharmaceuticals, Inc. (CRVS)
NASDAQ: CRVS · Real-Time Price · USD
8.81
0.00 (0.00%)
At close: Dec 5, 2025, 4:00 PM EST
9.08
+0.27 (3.06%)
After-hours: Dec 5, 2025, 7:01 PM EST
Corvus Pharmaceuticals Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Corvus Pharmaceuticals stock have an average target of 13.75, with a low estimate of 11 and a high estimate of 17. The average target predicts an increase of 56.07% from the current stock price of 8.81.
Analyst Consensus: Strong Buy
* Price targets were last updated on Oct 13, 2025.
Analyst Ratings
The average analyst rating for Corvus Pharmaceuticals stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 1 | 1 | 1 |
| Buy | 2 | 2 | 2 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Buy Initiates $16 | Buy | Initiates | $16 | +81.61% | Oct 13, 2025 |
| Mizuho | Mizuho | Buy Maintains $12 → $11 | Buy | Maintains | $12 → $11 | +24.86% | May 20, 2025 |
| Oppenheimer | Oppenheimer | Buy Reiterates $15 → $17 | Buy | Reiterates | $15 → $17 | +92.96% | May 9, 2025 |
| Oppenheimer | Oppenheimer | Buy Maintains $14 → $15 | Buy | Maintains | $14 → $15 | +70.26% | Mar 26, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $11 | Strong Buy | Reiterates | $11 | +24.86% | Mar 26, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.28
from -1.02
EPS Next Year
-0.59
from -0.28
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||
| Avg | n/a | n/a | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -0.12 | -0.53 | ||||
| Avg | -0.28 | -0.59 | ||||
| Low | -0.52 | -0.62 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.